NASDAQ:CYTK - Cytokinetics Stock Price, Forecast & News

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics, Inc. (NASDAQ:CYTK) posted its quarterly earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.06. The biopharmaceutical company earned $6.06 million during the quarter, compared to analysts' expectations of $7.80 million. Cytokinetics had a negative return on equity of 10,351.99% and a negative net margin of 378.70%. View Cytokinetics' Earnings History.

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Cytokinetics.

6 Wall Street analysts have issued twelve-month target prices for Cytokinetics' shares. Their forecasts range from $16.00 to $26.00. On average, they expect Cytokinetics' share price to reach $21.50 in the next year. This suggests a possible upside of 77.1% from the stock's current price. View Analyst Price Targets for Cytokinetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

Media stories about CYTK stock have trended very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cytokinetics earned a media sentiment score of 3.4 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Cytokinetics.

Cytokinetics saw a increase in short interest in December. As of December 31st, there was short interest totalling 9,400,000 shares, an increase of 6.7% from the December 15th total of 8,810,000 shares. Based on an average daily volume of 840,600 shares, the short-interest ratio is currently 11.2 days. Currently, 17.3% of the company's stock are short sold. View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include Genmab A/S (GMAB), Uniqure (QURE), Emergent Biosolutions (EBS), Biohaven Pharmaceutical (BHVN), Amicus Therapeutics (FOLD), Zogenix (ZGNX), ArQule (ARQL), ChemoCentryx (CCXI), Epizyme (EPZM), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT), Karuna Therapeutics (KRTX), Ra Pharmaceuticals (RARX), Synthorx (THOR) and Xencor (XNCR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Geron (GERN), Synergy Pharmaceuticals (SGYP) and TG Therapeutics (TGTX).

Cytokinetics' stock is owned by many different of institutional and retail investors. Top institutional investors include Mirador Capital Partners LP (0.17%), Louisiana State Employees Retirement System (0.03%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum and Value Fund L P Biotechnology. View Institutional Ownership Trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. Company insiders that have sold Cytokinetics company stock in the last year include Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.

CYTK stock was acquired by a variety of institutional investors in the last quarter, including Mirador Capital Partners LP and Nisa Investment Advisors LLC. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $12.14.

Cytokinetics has a market capitalization of $717.23 million and generates $31.50 million in revenue each year. The biopharmaceutical company earns $-106,290,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.View Additional Information About Cytokinetics.

The official website for Cytokinetics is http://www.cytokinetics.com/.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]